| Literature DB >> 26901036 |
Dhêmerson Souza de Lima1, Mauricio Morishi Ogusku2, Maisa Porto Dos Santos2, Cláudia Maria de Melo Silva3, Vanessa Alves de Almeida1, Irineide Assumpção Antunes4, Antonio Luiz Boechat1, Rajendranath Ramasawmy1,5,6, Aya Sadahiro1.
Abstract
Immunogenetic host factors are associated with susceptibility or protection to tuberculosis (TB). Strong associations of HLA class II genes with TB are reported. We analyzed the HLA-DRB1*04 alleles to identify subtypes associated with pulmonary TB and their interaction with risk factors such as alcohol, smoking, and gender in 316 pulmonary TB patients and 306 healthy individuals from the Brazilian Amazon. The HLA-DRB1*04 was prevalent in patients with pulmonary TB (p<0.0001; OR = 2.94; 95% CI = 2.12 to 4.08). Direct nucleotide sequencing of DRB1 exon 2 identified nine subtypes of HLA-DRB1*04. The subtype HLA-DRB1*04:11:01 (p = 0.0019; OR = 2.23; 95% CI = 1.34 to 3.70) was associated with susceptibility to pulmonary TB while DRB1*04:07:01 (p<0.0001; OR = 0.02; 95% CI = 0.001 to 0.33) to protection. Notably, the interaction between alcohol and HLA-DRB1*04:11:01 increased the risk for developing pulmonary TB (p = 0.0001; OR = 51.3; 95% CI = 6.81 to 386). Multibacillary pulmonary TB, the clinical presentation of disease transmission, was strongly associated with interaction to alcohol (p = 0.0026; OR = 11.1; 95% CI = 3.99 to 30.9), HLA-DRB1*04:11:01 (p = 0.0442; OR = 2.01; 95% CI = 1.03 to 3.93) and DRB1*04:92 (p = 0.0112; OR = 8.62; 95% CI = 1.63 to 45.5). These results show that HLA-DRB1*04 are associated with pulmonary TB. Interestingly, three subtypes, DRB1*04:07:01, DRB1*04:11:01 and DRB1*04:92 of the HLA-DRB1*04 could be potential immunogenetic markers that may help to explain mechanisms involved in disease development.Entities:
Mesh:
Substances:
Year: 2016 PMID: 26901036 PMCID: PMC4764689 DOI: 10.1371/journal.pone.0147543
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
General characteristics of patients with pulmonary TB and controls.
| Characteristics | Patients n = 316 | Controls n = 306 |
|---|---|---|
| Male, n (%) | 194 (61.4%) | 142 (46.4%) |
| Female, n (%) | 122 (38.6%) | 164 (53.6%) |
| Mean age ± SD | 36±12.6 | 35±10.7 |
| Yes, n (%) | 212 (67.0%) | 180 (58.8%) |
| No, n (%) | 25 (8.00%) | 36 (11.8%) |
| Data not available, n (%) | 79 (25.0%) | 90 (29.4%) |
| Yes, n (%) | 87 (27.5%) | 20 (6.50%) |
| No, n (%) | 135 (42.7%) | 226 (73.9%) |
| Data not available, n (%) | 94 (29.8%) | 60 (19.6%) |
| Yes, n (%) | 69 (21.8%) | 9 (3.00%) |
| No, n (%) | 153 (48.4%) | 233 (76.0%) |
| Data not available, n (%) | 94 (29.8) | 64 (21.0%) |
a Gender: (p = 0.0002; OR = 1.84; 95% IC = 1.33 to 2.53), calculated with Fisher’s exact test
b Alcoholic drink: Individuals who consumed ≥ 4 doses for women and ≥ 5 doses for men at the same time within the last 30 days [42]. 1 dose = 30 ml distilled (or 12 g of pure alcohol). p<0.0001; OR = 7.28; 95% CI = 4.28 to 12.4, calculated with Fisher’s exact test.
c Smoking: were defined as smokers, who made use of cigarettes daily for one year or more [43]. p<0.0001; OR = 11.7; 95% CI = 5.66 to 24.1, calculated with Fisher’s exact test.
Results of the obtained nucleotide sequences and aligned with the sequences of the IMGT/HLA.
| Alleles | Score | Length Obtained (IMGT) | Identities % | Positives % | Ethnic Origin IMGT/HLA |
|---|---|---|---|---|---|
| 1085 | 561 (801 bp) | 100 | 100 | Caucasoid, Oriental | |
| 1085 | 561 (801 bp) | 100 | 100 | Caucasoid | |
| 1085 | 561 (801 bp) | 100 | 100 | Caucasoid | |
| 1085 | 561 (801 bp) | 100 | 100 | Caucasoid | |
| 1085 | 561 (801 bp) | 100 | 100 | Caucasoid, Oriental | |
| 1085 | 561 (801 bp) | 100 | 100 | Caucasoid, Oriental | |
| 1076 | 561 (801 bp) | 99 | 99 | Caucasoid, Hispanic | |
| 1085 | 561 (801 bp) | 100 | 100 | Australian Aboriginal, H | |
| 1076 | 561 (663 bp) | 99 | 99 | Unknown |
a Hispanic: People historically of mixed Mediterranean Caucasoid, American Indian race
b Mixed: The mixture of various races
c Unknown: Ethnic origin unknown.
Distribution and association analysis of HLA-DRB1*04 subtypes in pulmonary TB patients and the control group.
| Alleles | Patientsn = 187 (%) | Controls n = 101 (%) | OR | 95% CI | |
|---|---|---|---|---|---|
| 6 (3.2) | 6 (5.9) | 0.3544 | 0.525 | 0.165 to 1.67 | |
| 9 (4.8) | 9 (8.9) | 0.2039 | 0.517 | 0.198 to 1.35 | |
| 9 (4.8) | 9 (8.9) | 0.2039 | 0.517 | 0.198 to 1.35 | |
| 42 (22.5) | 28 (27.7) | 0.3185 | 0.755 | 0.434 to 1.32 | |
| 2 (1.1) | 3 (3.0) | 0.3479 | 0.353 | 0.058 to 2.15 | |
| 3 (1.6) | 2 (2.0) | 1.0000 | 0.807 | 0.133 to 4.91 | |
| 0 (0.0) | 12 (11.9) | 0.0001 | 0.019 | 0.001 to 0.33 | |
| 95 (50.8) | 32 (31.7) | 0.0019 | 2.23 | 1.34 to 3.70 | |
| 21 (11.2) | 0 (0.0) | 0.0002 | 26.21 | 1.57 to 438 |
a Fisher’s exact test, p < 0.05; OR = Odds ratio; CI = Confidence interval
b Significant p values according to the Bonferroni correction (p<0.006)
Prediction of the binding for epitopes of ESAT-6 with HLA molecules encoded by HLA-DRB1*04:11:01 and DRB1*04:07:01.
| Alleles | AntigensStart-End | Sequences | Core regions | Percentile rank |
|---|---|---|---|---|
| ESAT-6 5–19 | QWNFAGIEAAASAIQ | FAGIEAAAS | 1.58 | |
| ESAT-6 4–18 | QQWNFAGIEAAASAI | FAGIEAAAS | 1.96 | |
| ESAT-6 6–20 | WNFAGIEAAASAIQG | FAGIEAAAS | 3.78 | |
| ESAT-6 3–17 | EQQWNFAGIEAAASA | FAGIEAAAS | 4.55 | |
| ESAT-6 7–21 | NFAGIEAAASAIQGN | FAGIEAAAS | 8.31 | |
| ESAT-6 2–16 | TEQQWNFAGIEAAAS | FAGIEAAAS | 9.92 | |
| ESAT-6 19–33 | QGNVTSIHSLLDEGK | VTSIHSLLD | 13.28 | |
| ESAT-6 18–32 | IQGNVTSIHSLLDEG | VTSIHSLLD | 13.54 | |
| ESAT-6 17–31 | AIQGNVTSIHSLLDE | VTSIHSLLD | 16.08 | |
| ESAT-6 62–76 | ATELNNALQNLARTI | LNNALQNLA | 16.22 | |
| ESAT-6 5–19 | QWNFAGIEAAASAIQ | FAGIEAAAS | 16.68 | |
| ESAT-6 16–30 | SAIQGNVTSIHSLLD | VTSIHSLLD | 16.71 |
Percentile rank ≤ 10.0—Lower percentile rank indicates the 15-mer peptides with higher affinity to HLA